High mobility group box 1 (HMGB1)
HMGB1 (high-mobility group box 1) is a highly conserved nuclear protein that functions primarily as a chromatin-associated DNA-binding factor, but it is also widely recognized as an extracellular signaling molecule.
HMGB1 (high-mobility group box 1) is a highly conserved nuclear protein that functions primarily as a chromatin-associated DNA-binding factor, but it is also widely recognized as an extracellular signaling molecule. In the nucleus, HMGB1 helps organize chromatin and modulate transcriptional accessibility. When released from stressed, damaged, or dying cells, it can act as an alarmin or damage-associated molecular pattern, promoting inflammatory signaling through receptors such as receptor for advanced glycation end products (RAGE) and, in broader inflammatory contexts, pathways involving toll like receptor 4 (TLR4).
In biomedical research, HMGB1 is frequently studied as a mediator of inflammation, tissue injury, and immunogenic cell death. Its extracellular release is often associated with immune activation, while intracellular regulation of HMGB1, including acetylation status and subcellular localization, can influence inflammatory outcomes. Because of these roles, HMGB1 has become a target of interest in cancer immunotherapy, sepsis, liver injury, disc degeneration, and neonatal inflammatory conditions.
Where the papers sit
8 papers from the last 6 months study High mobility group box 1 (HMGB1) directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 3 human data · 3 preclinical · 1 unclassified
Themes no clear themes
Those 8 do not share a common subject.
-
HMGB1 recurs as a circulating marker or inflammatory mediator across pulmonary hypertension, neonatal jaundice, cognitive impairment, PCOS, and several cancers. Mechanistic studies link it to ferroptosis, microglial inflammation, insulin resistance, radioresistance, immune suppression, and treatment response. Other reports use HMGB1 only as a clinical correlate or pathway component, including melanogenesis and phototherapy outcomes. The set has no shared disease question or consistent therapeutic direction.
Papers
The 8 papers from the last 6 months that study High mobility group box 1 (HMGB1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (8)
- Utility of serum HMGB1 in chronic obstructive pulmonary disease with pulmonary hypertension: A single-centre analysis. Pulmonology · 21 Aug 2026 PMID 42625546
- HMGB1 aggravates neuronal ferroptosis and microglial inflammation in metabolic syndrome-associated cognitive impairment via the NRF2-autophagic flux axis. Molecular biomedicine · 18 Aug 2026 PMID 42608631
- Co-delivery of glabridin and uralsaponin X with lipid nanoparticles inhibits melanogenesis and melanin transfer. Colloids and surfaces. B, Biointerfaces · 13 Jul 2026 PMID 42442171
- Targeting Long Noncoding RNA LUCAT1 Alleviates Insulin Resistance of Ovarian Granulosa Cells in Polycystic Ovary Syndrome by Blocking HMGB1-Mediated Autophagy. American journal of reproductive immunology (New York, N.Y. : 1989) · 1 Jul 2026 PMID 42381638
- Weekly measurement of HMGB1 during neoadjuvant chemoradiotherapy in rectal cancer patients: correlations with MRI response and ctDNA. Radiology and oncology · 26 Jun 2026 PMID 42359756
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
- WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
- Serum HMGB1 and sCD14 levels in neonates with jaundice: associations with disease severity and phototherapy efficacy. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 26 May 2026 PMID 42186388
By study type
Observational studies and case reports (1)
- Serum HMGB1 and sCD14 levels in neonates with jaundice: associations with disease severity and phototherapy efficacy. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 26 May 2026 PMID 42186388
Human data, design not indexed (3)
- Utility of serum HMGB1 in chronic obstructive pulmonary disease with pulmonary hypertension: A single-centre analysis. Pulmonology · 21 Aug 2026 PMID 42625546
- Targeting Long Noncoding RNA LUCAT1 Alleviates Insulin Resistance of Ovarian Granulosa Cells in Polycystic Ovary Syndrome by Blocking HMGB1-Mediated Autophagy. American journal of reproductive immunology (New York, N.Y. : 1989) · 1 Jul 2026 PMID 42381638
- Weekly measurement of HMGB1 during neoadjuvant chemoradiotherapy in rectal cancer patients: correlations with MRI response and ctDNA. Radiology and oncology · 26 Jun 2026 PMID 42359756
Preclinical: animal, cell and lab studies (3)
- HMGB1 aggravates neuronal ferroptosis and microglial inflammation in metabolic syndrome-associated cognitive impairment via the NRF2-autophagic flux axis. Molecular biomedicine · 18 Aug 2026 PMID 42608631
- Co-delivery of glabridin and uralsaponin X with lipid nanoparticles inhibits melanogenesis and melanin transfer. Colloids and surfaces. B, Biointerfaces · 13 Jul 2026 PMID 42442171
- WNK4 Enhances Anti-PD-1 Resistance and Promotes Tumor Progression in Hepatocellular Carcinoma by Reprogramming Cysteine Metabolism in Cancer-Associated Fibroblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42253146
Unclassified: not yet indexed with MeSH (1)
- EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.